AddedRisk Factors
Furthermore, our tax obligations (including the cost of compliance) and effective tax rate in the jurisdictions in which we conduct business could increase as a result of international tax developments, including the implementation of the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Two-Pillar” framework, which involves, among other measures, the imposition of a minimum effective corporate tax rate (referred to as Pillar Two). Certain countries in which we conduct business have enacted, or are in the process of enacting, core provisions of the Pillar Two rules (with further provisions expected to be enacted in the future). Based on our current understanding of the minimum revenue thresholds contained in the Pillar Two proposal, we currently expect to fall within the scope of its rules. The OECD has issued (and is expected to
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
continue to issue further) administrative guidance providing transition and safe harbor rules in relation to the implementation of the Pillar Two proposal. For example, on January 5, 2026, the OECD published details of a proposed “side-by-side” arrangement providing for, among other things, additional safe harbors for multinational groups headquartered in certain qualifying jurisdictions. We continue to evaluate and assess the potential impact of these new rules, including on our effective tax rate, and our eligibility to qualify for any transition relief or safe harbor (including under the proposed “side-by-side” arrangement). Any changes in tax laws, including any new tax laws or initiatives, could not only significantly increase our tax provision, cash tax liabilities, and effective tax rate, but could also have a material impact on the value of our deferred tax assets, result in significant one-time charges and ongoing compliance costs, and increase our future tax expense.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
•the perceived success of our plan to develop a steady cadence of innovative medicines for years to come;
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedRisk Factors
•developments related to the FDA, the Centers for Medicare & Medicaid Services (CMS) and foreign regulatory agencies;
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RemovedRisk Factors
Legislators, policymakers, and payors may continue to propose and implement cost-containing measures to keep healthcare costs down. These measures could include limitations on the prices we would be able to charge for product candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for these products from governmental authorities or third-party payors. Further, an increasing number of countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere, including in the U.S.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business. Any of these consequences could have an adverse effect on our results of operations and financial condition.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
On October 11, 2024, Kevin Gorman, Ph.D., retired as the Company's President and Chief Executive Officer and Kyle Gano, Ph.D., formerly our Chief Business Development and Strategy Officer, succeeded Dr. Gorman in the CEO role. Dr. Gano also joined our Board of Directors effective as of October 11, 2024. Dr. Gorman founded Neurocrine in 1992 and has held numerous positions across the Company, including Chief Operating Officer, Chief Business Officer, and Senior Vice President of Business Development, before being appointed CEO in 2008. Dr. Gano was appointed Neurocrine’s Chief Business Development Officer in 2011, and Chief Business Development and Strategy Officer in 2020, and is responsible for all of Neurocrine’s business and corporate development activities. Our Board of Directors worked closely with Dr. Gorman on succession planning and believes Dr. Gano and the senior leadership team are well-positioned to continue to execute our strategy. Although Dr. Gorman will continue to serve on our Board of Directors and provide strategic direction to the Company, this leadership transition may be viewed negatively by investors, our strategic partners, or other stakeholders. Further, if the transition is not managed effectively, it could disrupt our operations and impact our financial condition and results.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
•commercialize INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease;
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, the Tax Cuts and Jobs Act of 2017, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Among other changes, the Tax Cuts and Jobs Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the U.S. and over 15 years for research activities conducted outside the U.S. If the requirement to amortize research and development expenditures is not repealed or otherwise modified, it will continue to have an adverse effect on our tax liability. Furthermore, our tax obligations and effective tax rate in the jurisdictions in which we conduct business could increase as a result of international tax developments, including the implementation of the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Two-Pillar” framework, which involves the reallocation of taxing rights in respect of certain multinational enterprises above a fixed profit margin to the jurisdictions in which they carry on business (referred to as Pillar One) and the imposition of a minimum effective corporate tax rate (referred to as Pillar Two). Certain countries in which we conduct business have enacted, or are in the process of enacting, core provisions of the Pillar Two rules. We continue to evaluate and assess the potential impact of these new rules, including on our effective tax rate, and our eligibility to qualify for transition and safe harbor. Any changes in tax laws, including any new tax legislation or initiatives, could not only significantly increase our tax provision, cash tax liabilities, and effective tax rate, but could also have a material impact on the value of our deferred tax assets, result in significant one-time charges and ongoing compliance costs, and increase our future tax expense.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
The implementation of these cost containment measures may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs, particularly since the majority of our current revenue is derived from federal healthcare programs, including Medicare and Medicaid.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedRisk Factors
information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RewordedRisk Factors
We Our share repurchases may change from time to time, and we can provide no assurance that this we will repurchase shares of our common stock at favorable prices, in particular amounts, or future share at all, and any repurchases will may not enhance long-term stockholder value, and it may not value or prove to be the best use of our cash.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
The ability of the FDA or comparable foreign regulatory authorities Patent and Trademark Office and other government agencies to review and approve new products perform their normal business functions, can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of manage user fees, fee programs, and statutory, regulatory, and policy changes. changes (such as reductions in force).
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety products, and the ability of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. U.S.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, government funding of other government agencies or comparable foreign regulatory authorities on which our operations may rely, including Patent and Trademark Office, the Patent Trial and Appeal Board and those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have continued to invest in our commercial infrastructure and distribution capabilities, infrastructure, including the recent expansion of our psychiatry and long-term care sales teams for INGREZZA in September 2024. which we anticipate to be completed by the end of the first quarter of 2026.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates. candidates, which could adversely affect our business, results of operations and future growth prospects, and could cause the market price of our common stock to decline.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Changes in the FDA, Patent and Trademark Office, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent delay the development and commercialization of new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA and CRENESSITY, royalties from out-licensed products, the impact of Medicare Part D coverage, including redesign of the Part D benefit enacted as part of the Inflation Reduction Act, IRA, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, disruptions caused by geopolitical and macroeconomic developments, man-made or natural disasters, public health pandemics or epidemics, armed conflicts, trade restrictions, tariffs, the recent shutdown of the U.S. federal government and the resulting effects on its regulatory agencies, or other business interruptions.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any deficiencies in the design design, implementation, or subsequent upgrades of the ERP system could adversely affect the effectiveness of our internal control over financial reporting or our ability to accurately maintain our books and records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
The ACA This law was intended to broaden access to health insurance and reduce by reducing the number of uninsured individuals, reduce persons, reducing or constrain constraining the growth of healthcare spending, enhance enhancing remedies against fraud and abuse, add adding transparency requirements for the healthcare and health insurance industries, impose imposing taxes and fees on the health industry and impose imposing additional health policy reforms.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls and validation, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced U.S., state and non-U.S. regulations, and disruptions or delays caused by geopolitical and macroeconomic developments, man-made or natural disasters, public health pandemics or epidemics, armed conflicts, trade restrictions, tariffs, the recent shutdown of the U.S. federal government and the resulting effects on its regulatory agencies, or other business interruptions.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedRisk Factors
Certain of the diseases that INGREZZA, CRENESSITY, and our product candidates are being developed to address are in underserved and underdiagnosed populations. populations, and, in the case of CRENESSITY, patients may also be incorrectly coded or misclassified in medical and reimbursement records.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected increased net product sales of CRENESSITY, which was launched in the U.S. as a first-in-class FDA-approved treatment of CAH in December 2024, and INGREZZA, driven by record total prescriptions on strong patient demand, partially offset by a lower net price due to new market access investments to support long-term growth.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected increased net product sales of INGREZZA and increased royalties payable on net product sales of CRENESSITY. In addition, cost of revenues for 2025 excluded costs that were charged to R&D expense prior to FDA approval of CRENESSITY. As a result, this lower-cost drug product reduced our cost of revenues and improved related product gross margins for 2025. In future periods, we expect to incur a higher cost of revenues that includes the cost of CRENESSITY active pharmaceutical ingredients produced following FDA approval.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected higher headcount (including an increase of $22.2 million in non-cash stock-based compensation expense) to support our expanded discovery and preclinical programs across therapeutic areas and modalities, including endocrinology and metabolic disease (including obesity) and immunology, and expanding our capabilities in biologics (including peptides and antibodies) and gene therapy.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected higher upfront payments under licensing agreements for early-stage development candidates.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected increased total net product sales, partially offset by continued investments in our commercial organization (including the expansion of our psychiatry and long-term care sales teams completed in September 2024 and CRENESSITY-related headcount and commercial launch activities) and expanded pre-clinical and clinical portfolio. The increase in accounts receivable was driven by higher total gross product sales. The increase in accounts payable and accrued liabilities was driven primarily by higher revenue-related reserves for discounts and allowances attributed to higher gross product sales combined with expanded formulary access for INGREZZA. In addition, the change in income tax assets and liabilities primarily related to timing of foreign tax expense recognition, partially offset by the federal tax benefit on current income taxes payable from the enactment of the OBBBA.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
For 2025 compared to 2024, the change primarily reflected decreased share repurchases under the 2025 Repurchase Program compared to the 2024 Repurchase Program and decreased cash payments associated with the convertible senior notes that matured in May 2024.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
In addition to the foregoing future capital requirements, in February 2025, our Board of Directors authorized the 2025 Repurchase Program under which we may repurchase up to $500.0 million of our common stock, subject to market conditions. The 2025 Repurchase Program is in addition to the $300.0 million 2024 Repurchase Program that was announced in October 2024 and completed in February 2025. Under the 2025 Repurchase Program, we repurchased 1.5 million shares on the open market for a cost of $167.7 million during 2025. As of December 31, 2025, we had $332.3 million remaining available for additional repurchases under the 2025 Repurchase Program.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
AddedMD&A
We recognize a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority, based on the technical merits of the position. The tax benefit recognized in our consolidated financial statements for a particular tax position is measured as the largest amount of benefit that is more likely than not to be realized upon settlement with the relevant taxing authority. We reevaluate uncertain tax positions and related unrecognized tax benefits as appropriate for changes in facts and circumstances, including significant changes in tax law, regulations or interpretations, new information obtained during a tax examination, the resolution of tax examinations and appeals, and the expiration of statutes of limitations. We recognize accrued interest and penalties, when appropriate, related to uncertain tax positions in income tax expense. An adverse resolution of one or more uncertain tax positions, or changes in our assessment of the recognition or measurement of such positions, could have a material impact on our results of operations in the period in which the change occurs.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RemovedMD&A
For 2023 compared to 2022, the decrease primarily reflected decreased expense recognized in connection with development milestones achieved under our collaborations with Nxera, Xenon Pharmaceuticals Inc. (Xenon), and Takeda.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
For 2023 compared to 2022, the increase primarily reflected higher headcount and increased non-cash stock-based compensation expense primarily driven by a charge related to a change in equity grant agreement terms in 2023.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, (in millions) 2024 2023 2022 Selling, general, and administrative $ 1,007.2 $887.6 $752.7
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
For 2023 compared to 2022, the increase primarily reflected increased investment in our commercial initiatives, including our branded direct-to-consumer INGREZZA advertising campaign and deployment of our expanded salesforce completed in April 2022, and increased payroll and benefits expenses on higher headcount and increased non-cash stock-based compensation expense primarily driven by a charge related to a change in equity grant agreement terms in 2023.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
Year Ended December 31, (in millions) 2024 2023 2022 Provision for income taxes $ 144.7 $82.4 $59.4
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RemovedMD&A
Cash flows from financing activities for all periods presented reflected proceeds from issuances of our common stock.
Read it in 10-K Feb 10, 2025 at sec.govopen_in_new
RewordedMD&A
For 2024 2025 compared to 2023, 2024, the increase primarily reflected continued investment in our commercial organization, including organization (including the recent expansion of our psychiatry and long-term care sales team teams completed in September 2024, pre-launch CRENESSITY activities, increased facility expenses related to our new campus facility, 2024 and CRENESSITY-related headcount and commercial launch activities), partially offset by decreased impairment charges of $14.0 million associated with leased office space that has been our vacated as we continue to occupy our new legacy campus facility. facilities.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2022, 2025, the effective tax rate varied differed from the federal and state statutory rates primarily due to foreign tax effects, including the impact of global intangible low-taxed income (GILTI), credits generated for research activities and activities, excess tax benefits related to stock-based compensation, certain nondeductible expenses, and state income tax effects including the premium paid on the repurchase of the 2024 Notes fluctuations in 2022. state effective tax rates.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024 2025 compared to 2023, 2024, the increase in total other expense, net, change primarily reflected $138.4 million of expense recognized in connection prior year charges associated with conversions of the 2024 Notes upon maturity convertible senior notes that matured in May 2024 and periodic fluctuations in the fair values of our equity investments, partially offset by increased interest income on our debt security investments.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024 compared to 2023, the increase primarily reflected continued investment in our commercial organization, including organization (including the recent expansion of our psychiatry and long-term care sales team teams completed in September 2024, 2024 and CRENESSITY-related pre-launch CRENESSITY activities, activities), increased facility facility-based expenses related to our new campus facility, and impairment charges of $14.0 million associated with leased office space that has been our vacated as we continue to occupy our new legacy campus facility. facilities.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024 compared to 2023, the increase in total other expense, net, change primarily reflected $138.4 million of expense recognized in connection associated with conversions of the 2024 Notes upon maturity convertible senior notes that matured in May 2024 and 2024, periodic fluctuations in the fair values of our equity investments, partially offset by and increased interest income on our debt security investments.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024 compared to 2023, the decrease primarily reflected lower spend on certain early-stage programs in epilepsy and psychiatry, psychiatry programs, including the successful completions of the Phase 2 programs for osavampator in MDD and NBI-1117568 direclidine in schizophrenia, partially offset by increased investments in the Phase 2 program for NBI-1070770 in MDD and certain early-stage psychiatry programs and our early-stage muscarinic programs. portfolio.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2023 2025 compared to 2022, 2024, the increase primarily reflected increased investments in certain early-stage the Phase 3 programs for osavampator in psychiatry, MDD and direclidine in schizophrenia, partially offset by lower spend on early-stage programs crinecerfont in epilepsy. CAH.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in (dollars in millions) 2025 2024 2023 2022 Acquired in-process research and development $ 17.4 $ 12.5 $143.9 $ 143.9 as a % of total revenues 0.6 % 0.5 % 7.6 %
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Periodic fluctuations for all periods presented For 2025 compared to 2024 and 2024 compared to 2023, the changes primarily reflected timing differences related to our the purchases, sales, and maturities of debt security investments and changes in our portfolio-mix.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Research and discovery consists of costs incurred prior to the approval of an investigational new drug application by the applicable regulatory agency. agency, including discovery research and preclinical development activities (such as lead optimization, nonclinical studies, preclinical manufacturing, and toxicology).
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
For 2024 compared to 2023, the decrease primarily reflected the impact of decreased ONGENTYS® (opicapone) net product sales of ONGENTYS® (opicapone) and lower decreased ONGENTYS inventory reserves in connection with the termination of our license agreement with BIAL, which became effective in December 2023, partially offset by the impact of increased INGREZZA net product sales. sales of INGREZZA.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, (in millions) 2025 2024 2023 2022 Unrealized (loss) gain on equity investments $ (4.0) $ (37.1) $ 28.4 $ 30.8 Charges associated with convertible senior notes — (138.4) — (70.0) Investment income and other, net 90.3 91.0 52.8 4.1 Total other (expense) income, income (expense), net $ 86.3 $ (84.5) $ 81.2 $ (35.1)
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new
Quiet changesMD&A
For 2024 compared to 2023, the increase primarily reflected increased investments in gene therapy and other preclinical development programs.
Read it in 10-K Feb 11, 2026 at sec.govopen_in_new